

Product Name: KN-93 Phosphate Revision Date: 01/10/2020

# **Product Data Sheet**

# **KN-93 Phosphate**

**Cat. No.:** B4969

CAS No.: 1188890-41-6

Formula: C26H32CIN2O8PS


**M.Wt:** 599.03

Synonyms:

Target: Others

Pathway: CaM kinase II

Storage: Store at -20°C



# Solvent & Solubility

≥29.95mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Mass			
	Solvent	1mg	5mg	10mg
	Concentration			
	1 mM	1.6694 mL	8.3468 mL	16.6937 mL
	5 mM	0.3339 mL	1.6694 mL	3.3387 mL
-10	10 mM	0.1669 mL	0.8347 mL	1.6694 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Shortsummary	CaM kinase II inhibitor, water soluble and cell permeable
IC <sub>50</sub> & Target	

In Vitro

Cell Viability Assay		
Cell Line:	Human hepatic stellate cell line LX-2	
Preparation method:	Soluble in DMSO >30mg/mL. General tips for obtaining a higher concentration:  Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.	
Reacting conditions:	ns: 5, 10, 25, 50µmol/L for 24h; 10 µmol/L for 4, 8, 16, 24, 48h	
Applications:	KN-93 decreased the proliferation of human hepatic stellate cells in a dose dependent manner after 24 h treatment. Incubation of 10 µmol/L KN-93	

		induced the cell growth reduction in a time-dependent manner. KN-93 reduced			
		the expression of p53 and p21.			
	Animal experiment	Animal experiment			
In Vivo	Animal models:	adult Sprague Dawley female rats (model of PD was induced by			
	.0	6-hydroxydopamine (OHDA))			
	Dosage form:	1μg, 2μg, or 5μg KN-93, intrastriatal injections			
	Applications:	The data indicated that intrastriatal injections of KN-93 were beneficial in			
		reducing the expression of LID (levodopa-induced dyskinesia) by lowering the			
		expression of pGluR1S845(Phosphorylated GluR1(Glutamate receptor 1) at			
		Serine-845) via suppressing the activation of CaMKII (calcium -dependent			
		protein kinase II) in PD rats. Decreased expression of pGluR1S845 further			
		reduced the expression of Gad1(glutamate decarboxylase 1) and			
		nr4a1(nuclear receptor subfamily 4, group A, member 1) in PD rats.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
	40.	slightly differ with the theoretical value. This is caused by an experimental			
	The Unitrolin	system error and it is normal.			

## **Product Citations**

See more customer validations on www.apexbt.com.

### References

- [1]. An P, Zhu JY, et al, KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007 Mar 7;13(9):1445-8.
- [2]. Yang X, Wu N, et al, Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat. 2013;9:1213-20. doi: 10.2147/NDT.S45422.

### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

## **APExBIO Technology**

### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



Tomas Partition Experience and Conference

APE I TO THE STATE OF THE STATE

APENDER BIO

APE BOOK TO STORY

A P E Laborator Laborator de Constitución de la Con

APEN ARGONICA DE LA COMPANIA DEL COMPANIA DE LA COMPANIA DEL COMPANIA DE LA COMPA